|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2000-11-27
|
|
pubmed:abstractText |
To determine the safety and potential clinical efficacy of primary and booster injections of a DR4/1 peptide in patients with active rheumatoid arthritis (RA) despite methotrexate therapy. METHODS. Subjects with active RA were enrolled in a randomized, placebo controlled, double blind, dose-escalating clinical trial of synthetic DR4/1 peptide containing the shared epitope. The primary injection of the DR4/1 peptide in alum adjuvant was administered at one of 3 doses, 1.3, 4.0, and 13 mg, followed by up to 3 or 4 booster injections every 6 or 8 weeks at the same dose. The primary outcomes were the occurrence of adverse effects and changes in measures of immune function. Clinical efficacy was assessed using the American College of Rheumatology 20% criteria for clinical improvement.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0315-162X
|
|
pubmed:author |
pubmed-author:CohenS BSB,
pubmed-author:FleischmannR MRM,
pubmed-author:HolcenbergJ SJS,
pubmed-author:IGELLL,
pubmed-author:LeeM LML,
pubmed-author:LeeS HSH,
pubmed-author:MorelandL WLW,
pubmed-author:OlsenN JNJ,
pubmed-author:PrattP WPW,
pubmed-author:ShulmanM JMJ,
pubmed-author:St ClairE WEW,
pubmed-author:WinkelhakeJJ,
pubmed-author:YocumD EDE
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1855-63
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:10955324-Adolescent,
pubmed-meshheading:10955324-Adult,
pubmed-meshheading:10955324-Aged,
pubmed-meshheading:10955324-Arthritis, Rheumatoid,
pubmed-meshheading:10955324-B-Lymphocytes,
pubmed-meshheading:10955324-Double-Blind Method,
pubmed-meshheading:10955324-Drug Therapy, Combination,
pubmed-meshheading:10955324-Female,
pubmed-meshheading:10955324-Flow Cytometry,
pubmed-meshheading:10955324-HLA-DR4 Antigen,
pubmed-meshheading:10955324-Humans,
pubmed-meshheading:10955324-Immunization, Secondary,
pubmed-meshheading:10955324-Injections, Intramuscular,
pubmed-meshheading:10955324-Lymphocyte Activation,
pubmed-meshheading:10955324-Lymphocyte Count,
pubmed-meshheading:10955324-Male,
pubmed-meshheading:10955324-Methotrexate,
pubmed-meshheading:10955324-Middle Aged,
pubmed-meshheading:10955324-Monocytes,
pubmed-meshheading:10955324-Oligopeptides,
pubmed-meshheading:10955324-Receptors, Antigen, T-Cell, alpha-beta,
pubmed-meshheading:10955324-Safety,
pubmed-meshheading:10955324-T-Lymphocytes,
pubmed-meshheading:10955324-Treatment Outcome
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Treatment of rheumatoid arthritis with a DR4/1 peptide.
|
|
pubmed:affiliation |
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. stcla003@mc.duke.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
